Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
https://www.zacks.com/stock/news/2210152/merck-mrk-keytruda-ok-d-by-fda-for-expanded-cervical-cancer-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210152
Jan 15, 2024 - FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.
0
Regeneron (REGN) Is Up 3.97% in One Week: What You Should Know
https://www.zacks.com/stock/news/2209670/regeneron-regn-is-up-3-97-in-one-week-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_10-2209670
Jan 12, 2024 - Does Regeneron (REGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
0
Biotech Stock Roundup: REGN Down on Eylea Update, MRNA Gains on Preliminary Results
https://www.zacks.com/stock/news/2208960/biotech-stock-roundup-regn-down-on-eylea-update-mrna-gains-on-preliminary-results?cid=CS-ZC-FT-analyst_blog|stock_roundup-2208960
Jan 11, 2024 - Preliminary Q4 and 2023 results from Regeneron (REGN) and Moderna (MRNA) were key highlights this week in the biotech sector.
0
GSK to Buy Private Biotech, Strengthen Respiratory Pipeline
https://www.zacks.com/stock/news/2208092/gsk-to-buy-private-biotech-strengthen-respiratory-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208092
Jan 10, 2024 - GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.
0
Select Medical (SEM) Unveils Separation Plan for Concentra
https://www.zacks.com/stock/news/2205808/select-medical-sem-unveils-separation-plan-for-concentra?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205808
Jan 04, 2024 - Select Medical (SEM) intends to separate its Concentra business in a bid to enhance shareholder value and boost growth prospects of strategically prioritized areas.
0
Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?
https://www.zacks.com/stock/news/2205668/are-medical-stocks-lagging-aclaris-therapeutics-acrs-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2205668
Jan 04, 2024 - Here is how Aclaris Therapeutics (ACRS) and Regeneron (REGN) have performed compared to their sector so far this year.
0
Earnings Estimates Moving Higher for Regeneron (REGN): Time to Buy?
https://www.zacks.com/stock/news/2205196/earnings-estimates-moving-higher-for-regeneron-regn-time-to-buy?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-2205196
Jan 03, 2024 - Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
0
Best Momentum Stocks to Buy for January 3rd
https://www.zacks.com/commentary/2204746/best-momentum-stocks-to-buy-for-january-3rd?cid=CS-ZC-FT-zacks_1_rank_additions|momentum_additions-2204746
Jan 03, 2024 - SRPT, WING and REGN made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 3, 2024.
0
Top 5 Momentum Picks for January After a Fabulous 2023
https://www.zacks.com/stock/news/2204856/top-5-momentum-picks-for-january-after-a-fabulous-2023?cid=CS-ZC-FT-analyst_blog|investment_ideas-2204856
Jan 03, 2024 - We have narrowed our search to five large-cap stocks that have strong momentum for January. These are BGNE, SHOP, REGN, SPLK and CASY.
0
5 Big Drug Stocks That May Continue to Outperform in 2024
https://www.zacks.com/stock/news/2199316/5-big-drug-stocks-that-may-continue-to-outperform-in-2024?cid=CS-ZC-FT-analyst_blog|investment_ideas-2199316
Dec 18, 2023 - Novo Nordisk (NVO), Eli Lilly (LLY), Vertex Pharmaceuticals (VRTX), Regeneron (REGN) and GSK (GSK) have been performing well this year. These stocks are poised to keep the momentum alive in 2024.
0